Ionis Pharmaceuticals (IONS) Holdings Reduced by California State Teachers Retirement System

California State Teachers Retirement System reduced its holdings in Ionis Pharmaceuticals (NASDAQ:IONS) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 195,850 shares of the company’s stock after selling 3,063 shares during the period. California State Teachers Retirement System’s holdings in Ionis Pharmaceuticals were worth $9,851,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IONS. The Manufacturers Life Insurance Company increased its position in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the period. Crossmark Global Holdings Inc. bought a new position in Ionis Pharmaceuticals in the 3rd quarter worth approximately $254,000. Sei Investments Co. increased its position in Ionis Pharmaceuticals by 8.7% in the 3rd quarter. Sei Investments Co. now owns 55,849 shares of the company’s stock worth $2,832,000 after buying an additional 4,492 shares during the period. New York State Common Retirement Fund increased its position in Ionis Pharmaceuticals by 1.0% in the 3rd quarter. New York State Common Retirement Fund now owns 387,492 shares of the company’s stock worth $19,646,000 after buying an additional 4,000 shares during the period. Finally, Quantbot Technologies LP bought a new position in Ionis Pharmaceuticals in the 3rd quarter worth approximately $243,000. 90.71% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Ionis Pharmaceuticals stock opened at $47.74 on Friday. The company has a debt-to-equity ratio of 1.45, a current ratio of 5.20 and a quick ratio of 5.15. The company has a market capitalization of $6,367.97, a price-to-earnings ratio of -1,193.20 and a beta of 2.44. Ionis Pharmaceuticals has a one year low of $37.26 and a one year high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.10. The business had revenue of $172.00 million for the quarter, compared to analyst estimates of $126.38 million. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. Ionis Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 EPS. equities analysts forecast that Ionis Pharmaceuticals will post -0.13 earnings per share for the current year.

Several analysts have recently weighed in on the company. Zacks Investment Research raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 9th. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 9th. ValuEngine raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 8th. TheStreet lowered Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a report on Tuesday, February 27th. Finally, BMO Capital Markets lifted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $51.12.

In related news, Director Joseph Klein III sold 3,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $48.99, for a total value of $146,970.00. Following the sale, the director now owns 11,339 shares of the company’s stock, valued at approximately $555,497.61. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director B Lynne Parshall sold 5,986 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total value of $309,835.36. Following the completion of the transaction, the director now directly owns 44,166 shares in the company, valued at approximately $2,286,032.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,635 shares of company stock worth $5,615,581. 2.13% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3298343/ionis-pharmaceuticals-ions-holdings-reduced-by-california-state-teachers-retirement-system.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whitbread  PT Raised to GBX 4,950
Whitbread PT Raised to GBX 4,950
Lennox International  Rating Reiterated by Stifel Nicolaus
Lennox International Rating Reiterated by Stifel Nicolaus
Allscripts  Now Covered by JPMorgan Chase
Allscripts Now Covered by JPMorgan Chase
Floor & Decor  PT Raised to $50.00 at Loop Capital
Floor & Decor PT Raised to $50.00 at Loop Capital
iQIYI  Coverage Initiated at Citigroup
iQIYI Coverage Initiated at Citigroup
TriState Capital  Rating Increased to Hold at Zacks Investment Research
TriState Capital Rating Increased to Hold at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.